載入...
DISSOLUTION PROFILE STUDY FOR INNOVATION ANTI-RETROVIRAL DRUG PRODUCT NIKAVIR® AND ITS FIXED COMBINATION WITH LAMIVUDINE (PHOSPHALADINE®)
Biopharmaceutical solubility was experimentally determined for innovation anti-retroviral API phosphazide (Nikavir®) which was classified as BCS Class 3 drug. Dissolution profile test for Nikavir® 200 mg and 400 mg in three media pH 1.2, 4.5, 6.8 was conducted, and equivalence for both dosages was s...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Russo |
| 出版: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
| 叢編: | Разработка и регистрация лекарственных средств |
| 主題: | |
| 在線閱讀: | https://www.pharmjournal.ru/jour/article/view/94 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|